Phase II Investigator-initiated Trial of Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)
This study is an open-label, parallel, 2-cohort, multicenter, investigator-initiated Phase 2 trial to evaluate the efficacy and safety of binimetinib in patients with advanced or recurrent low-grade glioma or pancreatic cancer harboring BRAF fusion/rearrangement.
NCT06159478 — Pancreatic Cancer
Status: Recruiting
http://inclinicaltrials.com/pancreatic-cancer/NCT06159478/
Explorations of Cell-free DNA Multi-omics Technology in Detection of Minimal Residual Disease and Disease Prognosis After Surgery in Early Pancreatic Ductal Adenocarcinoma: A Single-center, Prospective, Observational Case Study
This trial aims to develop a minimal residual disease (MRD) detection model for predicting recurrence of patients with stage I-II pancreatic ductal adenocarcinoma after surgery and adjuvant therapy, based on cfDNA fragmentation and methylation signal.
NCT06151691 — Pancreatic Ductal Adenocarcinoma
Status: Not yet recruiting
http://inclinicaltrials.com/pancreatic-ductal-adenocarcinoma/NCT06151691/
A Single-arm, Exploratory Clinical Study of Trilaciclib Combined With mFOLFIRINOX Regimen in the Treatment of Patients With Advanced Pancreatic Cancer
To observe the incidence of chemotherapy-induced myelosuppression and the safety of Trilaciclib combined with mFOLFIRINOX in patients with advanced pancreatic cancer receiving first-line treatment.
NCT06151262 — Pancreatic Cancer
Status: Recruiting
http://inclinicaltrials.com/pancreatic-cancer/NCT06151262/
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
This study aims to facilitate discovery and validation of tests for early detection in subjects at high risk for pancreatic ductal adenocarcinoma (PDAC) and to facilitate the use of state-of-the-art machine learning-based algorithms that utilize databases and images with the purpose of identifying early stages of pancreatic cancer, as well as people at high-risk.The study also aims to provide a platform for development of an interventional protocol for early detection of PDAC.
NCT06151223 — Pancreatic Cancer
Status: Recruiting
http://inclinicaltrials.com/pancreatic-cancer/NCT06151223/
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer
The purpose of this study is to evaluate the efficacy of mFOLFIRINOX plus radiotherapy to Patients with CA19-9-normal Advanced Pancreatic Cancer.
NCT06149689 — Pancreatic Adenocarcinoma
Status: Recruiting
http://inclinicaltrials.com/pancreatic-adenocarcinoma/NCT06149689/
Precision Imaging for Early Detection and Targeted Treatment Monitoring in Pancreatic Cancer
Specifically, in this project, the objective will be developped a model to capture imaging-based tumor heterogeneity with multiscale radiomics approach by obtaining the mirror tumor image at in vivo MRI, ex vivo MRI at histology. This imaging model giving a perfect virtual histology tumor representation will be secondary implemented on routine in vivo clinical MRI for early cancer detection and treatment monitoring. Successful completion of this proposal will lead to a comprehensive non invasive characterisation of pancreatic cancer and will be a game changer in patient management.
NCT06144762 — Pancreas Cancer
Status: Recruiting
http://inclinicaltrials.com/pancreas-cancer/NCT06144762/
Phase 1/2 Trial of Radiotherapy in Combination With TTI-101 in Patients With Borderline Resectable Pancreatic Cancer
To evaluate the safety, tolerability, and efficacy of TTI-101 given in combination with Stereotactic Body Radiation Therapy (SBRT) in borderline resectable pancreatic ductal adenocarcinoma.
NCT06141031 — Pancreatic Cancer
Status: Recruiting
http://inclinicaltrials.com/pancreatic-cancer/NCT06141031/
Early-stage Detection of LIver, Biliary tRAct and pancReatic Cancers by Liquid biopsY in Periphheral Blood: a Prospective Study (LIBRARY Study)
LIBRARY is a prospective, multi-center, observational study aimed at detecting early liver, biliary tract, and pancreatic cancers by combining assays of cell-free DNA (cfDNA) methylation, serum protein, and microRNA.
NCT06139042 — Pancreatic Cancer
Status: Recruiting
http://inclinicaltrials.com/pancreatic-cancer/NCT06139042/
An Open-label, Randomized, Multicenter, Phase II Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers
- Clinical trial phase: Phase 2 - Intervention model: Control group - Group allocation: Randomized controlled trial - Research perspective: Prospective study - Participating centers: Multicenter study - Definition of the intervention period: Based on the RECIST 1.1 guidelines, patients will receive treatment until dropout due to disease progression or unacceptable toxicity related to the trial drug. Patients will be followed up with to assess survival every 2 months until either death or the end of the trial, whichever is first. - The intervention period is from the date of IRB approval to December 31st, 2025 - The follow-up duration is one year, and the statistical analysis duration is six months - The total research period is from the date of IRB approval to June 30th, 2026
NCT06135896 — Unresectable Pancreatic Cancer
Status: Not yet recruiting
http://inclinicaltrials.com/unresectable-pancreatic-cancer/NCT06135896/
PROACTIVE Pilot Study: Pancreatic Resection Outcomes in Locally Advanced Pancreatic Cancer Involving Visceral Arteries Treated With Neoadjuvant Chemotherapy
This clinical trial tests how well surgical resection after chemotherapy given before surgery to make the tumor smaller (neoadjuvant) works to treat pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced) and that cannot be removed by surgery (unresectable). In general, surgery is considered the most effective treatment for pancreatic cancer, especially when the cancer is localized and has not spread to other organs. However, most patients with pancreatic cancer are not candidates for surgical removal because the cancer has grown into or close to nearby arteries, veins, or organs and there is a concern of damaging these nearby structures. Researchers want to find out if surgery after neoadjuvant chemotherapy can be done safely to completely remove the tumor in patients with locally advanced and unresectable pancreatic cancer.
NCT06132087 — Locally Advanced Pancreatic Adenocarcinoma
Status: Recruiting
http://inclinicaltrials.com/locally-advanced-pancreatic-adenocarcinoma/NCT06132087/